Advertisement

Topics

Paion: Hammer-News beflügeln Kurs!

01:19 EDT 3 Jul 2017 | FinanzNachrichten

Liebe Leser, die hinter uns liegende Handelswoche war für Paion-Aktionäre höchst erfreulich. Nachdem das Unternehmen "positive Headline-Daten" der laufenden Phase III-Studie von Remimazolam bekannt...

Original Article: Paion: Hammer-News beflügeln Kurs!

NEXT ARTICLE

More From BioPortfolio on "Paion: Hammer-News beflügeln Kurs!"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...